RetiSpec is a medical imaging company using advanced Artificial Intelligence to develop a screening tool for early and accurate detection of Alzheimer’s disease markers in the eye.
RetiSpec’s proprietary technology provides a non-invasive and more widely available solution for the early detection of Alzheimer’s disease than current methods of assessment.
Field: Medical Imaging
Headquarters: Toronto, ON
CEO & Co-founder
Eliav is a biomedical engineer with 7+ years experience managing R&D projects and having led several medical products from ideation to launch. He holds a BSc and MSc in Biomedical Engineering from Tel-Aviv University.
Head of Clinical Operations & Partnerships
Catherine is a health scientist and MBA with 10+ years of experience leading large-scale health research operations. In 2019, she was named one of the 100 Best & Brightest Executive MBAs globally by Poets & Quants.
Head of AI
Alon is an expert in artificial intelligence, deep learning and machine learning, and is a computer-vision researcher with over 10 years of industry experience, which includes designing two FDA approved AIs.
Ocular Imaging Specialist
Mailis is an expert in ophthalmic imaging. After a PhD in Molecular Biology and a successful post-doctoral fellowship at the University of Toronto, she combines her background in research with 6 years of clinical experience.
COO & Co-founder
Roy is a biomedical engineer, and an MBA. With 10 years of experience building new initiatives and working with ventures, Roy has led new technologies and early stage startups to market.
Adam has 7 years of hands-on experience in both fundamental and applied optics research, including bio-imaging, spectral analysis, and development of optical instrumentation.
Jared is an experienced data scientist with a background in medical biophysics and expertise in machine learning techniques.
Board of Directors
Founder & Managing Partner, iGan Partners
Sam is the Founder and Managing Partner of iGan Partners and has over 20 years of entrepreneurial, technology and venture capital experience. Sam founded iGan Partners in 2013 and is now the largest healthcare venture capital investor in Canada.
GM, Single Port Division, Intuitive
Iman was the youngest VP – and the only female to hold the role on the technology side of the business – at Intuitive, makers of the da Vinci surgical systems and pioneers in robotic-assisted surgery. She is an engineer with over 20 years experience in new product introduction, scaling, and contracting. She was named to Silicon Valley Business Journal's 40 Under 40 in 2019.
Vice President of New Markets, Gentex Corporation
Robert leads the strategic development of new markets, technologies, and partnerships that can grow to provide a secure and substantial future for Gentex’s products and team. Prior to this role, Robert has held various positions in Finance, Operations, Business Management and Executive Leadership.
Executive Director & Chief Science Officer, Alzheimer’s Drug Discovery Foundation (Observer)
Dr. Fillit is the Founding Executive Director and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). He is a Neuroscientist, geriatrician, and innovative philanthropy executive. He is a fellow of the American Geriatrics Society, the American College of Physicians, the Gerontological Society of America and the New York Academy of Medicine. Dr. Fillit earned his bachelor of arts in neurobiology cum laude from Cornell University and his medical degree from the SUNY-Upstate Medical University.
Kevin Anderson, BBA
Senior Manager Technology Licensing, University of Minnesota (Observer)
Kevin has over 20 years’ experience in the medical industry in sales, product management, training, and business development. He has worked in large and specialty pharmaceutical companies. Throughout his career, he’s launched over 20 new products in various commercialization leadership roles.
Principal, iGan Partners (Observer)
Billy is an investment leader in deal sourcing, structuring, and diligence activities. He works closely with iGan Partners’ portfolio operations, actively supporting new transactions (financings and acquisitions) and strategic planning initiatives. He sits on the boards of several leading Digital Health and MedTech companies.